Humira One Year Out: The Largest LOE Event In US Pharma History
Amgen’s Amjevita Biosimilar Set To Launch On 31 January 2023 With Many More To Follow
Executive Summary
Ahead of the first biosimilar Humira product set to launch in less than a year, In Vivo provides a comprehensive run-down of where biosimilar sponsors stand and the key issues ahead of market formation.
You may also be interested in...
FDA To Review Pfizer’s Abrilada For Humira Interchangeability
The US FDA is reviewing Pfizer’s Humira biosimilar, Abrilada, to assess whether the compound can be granted an interchangeability designation with the original drug.
AbbVie Maintains US Humira Erosion Belief As 2023 Negotiations Near
AbbVie is not yet changing its modelling for Humira’s erosion in 2023, when as many as nine competing biosimilars could launch. The originator stated however that it will be in a better position to comment when it “goes through negotiations this summer” with payers and insurance providers.
Teva Confident On US Adalimumab Filing Amid Alvotech Advantages
A delay in FDA approval for partner Alvotech’s proposed high-concentration biosimilar version of Humira has not concerned Teva, especially after the product was approved by the EMA at the end of last year. There “shouldn’t really be any challenges here,” management says.